Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia

Giuseppe Landonio, Paola Cinque, Annamaria Nosari, Sergio Gafa, Francesco Rizzo, Massimo Coen, Umberto Tirelli, Liliana Caggese, Umberto Di Luzio Paparatti, Adriano Lazzarin

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: To compare the effect of two dose regimens of zidovudine in the treatment of severe HIV-related thrombocytopenia (TP). Design: Eighty-four patients with severe HIV-related TP and platelet counts <50 × 109/l were enrolled in an open study at six centres. Patients were randomized into two groups to receive zidovudine (group A, 500 mg per day; group B, 1000 mg per day) for 6 months. Methods: Platelet counts were determined monthly and patients categorized as complete responders (CR; platelets > 100 × 109/l), partial responders (PR; platelets > 50 to <100 × 109/l), or failures (F; platelets to <50 × 109/l). CD4+ and CD8+ lymphocytes, HIV antigenaemia, β2-microglobulin, white blood cells, mean cell volume and haemoglobin were also determined. Results: Seventy-one patients (35 and 36 in groups A and B, respectively) completed the study; 11.4% of group A patients were CR and 45.7% PR; 38.9% of group B were CR and 33.3% PR. Increase in mean platelet counts was dose-related, more rapid in the higher dose group and remained significantly higher after 6 months of treatment (56.4 × 109/l in group A versus 98.2 × 109/l in group B; P <0.01). Conclusions: The results confirm the efficacy of zidovudine in the treatment of severe HIV-related TP. The average for CR and PR in the two groups was 64.8%; the higher dose of zidovudine was more effective at increasing platelet counts.

Original languageEnglish
Pages (from-to)209-212
Number of pages4
JournalAIDS (London, England)
Volume7
Issue number2
Publication statusPublished - Feb 1993

Fingerprint

Zidovudine
Platelet Count
Thrombocytopenia
Multicenter Studies
HIV
Blood Platelets
HIV-2
Erythrocyte Indices
Hemoglobins
Leukocytes
Therapeutics
Lymphocytes

Keywords

  • Dose
  • HIV-related thrombocytopenia
  • Therapy
  • Zidovudine

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia. / Landonio, Giuseppe; Cinque, Paola; Nosari, Annamaria; Gafa, Sergio; Rizzo, Francesco; Coen, Massimo; Tirelli, Umberto; Caggese, Liliana; Paparatti, Umberto Di Luzio; Lazzarin, Adriano.

In: AIDS (London, England), Vol. 7, No. 2, 02.1993, p. 209-212.

Research output: Contribution to journalArticle

Landonio, G, Cinque, P, Nosari, A, Gafa, S, Rizzo, F, Coen, M, Tirelli, U, Caggese, L, Paparatti, UDL & Lazzarin, A 1993, 'Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia', AIDS (London, England), vol. 7, no. 2, pp. 209-212.
Landonio, Giuseppe ; Cinque, Paola ; Nosari, Annamaria ; Gafa, Sergio ; Rizzo, Francesco ; Coen, Massimo ; Tirelli, Umberto ; Caggese, Liliana ; Paparatti, Umberto Di Luzio ; Lazzarin, Adriano. / Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia. In: AIDS (London, England). 1993 ; Vol. 7, No. 2. pp. 209-212.
@article{c5fade21c2e04d70a56f84aac40dfda2,
title = "Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia",
abstract = "Objective: To compare the effect of two dose regimens of zidovudine in the treatment of severe HIV-related thrombocytopenia (TP). Design: Eighty-four patients with severe HIV-related TP and platelet counts <50 × 109/l were enrolled in an open study at six centres. Patients were randomized into two groups to receive zidovudine (group A, 500 mg per day; group B, 1000 mg per day) for 6 months. Methods: Platelet counts were determined monthly and patients categorized as complete responders (CR; platelets > 100 × 109/l), partial responders (PR; platelets > 50 to <100 × 109/l), or failures (F; platelets to <50 × 109/l). CD4+ and CD8+ lymphocytes, HIV antigenaemia, β2-microglobulin, white blood cells, mean cell volume and haemoglobin were also determined. Results: Seventy-one patients (35 and 36 in groups A and B, respectively) completed the study; 11.4{\%} of group A patients were CR and 45.7{\%} PR; 38.9{\%} of group B were CR and 33.3{\%} PR. Increase in mean platelet counts was dose-related, more rapid in the higher dose group and remained significantly higher after 6 months of treatment (56.4 × 109/l in group A versus 98.2 × 109/l in group B; P <0.01). Conclusions: The results confirm the efficacy of zidovudine in the treatment of severe HIV-related TP. The average for CR and PR in the two groups was 64.8{\%}; the higher dose of zidovudine was more effective at increasing platelet counts.",
keywords = "Dose, HIV-related thrombocytopenia, Therapy, Zidovudine",
author = "Giuseppe Landonio and Paola Cinque and Annamaria Nosari and Sergio Gafa and Francesco Rizzo and Massimo Coen and Umberto Tirelli and Liliana Caggese and Paparatti, {Umberto Di Luzio} and Adriano Lazzarin",
year = "1993",
month = "2",
language = "English",
volume = "7",
pages = "209--212",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia

AU - Landonio, Giuseppe

AU - Cinque, Paola

AU - Nosari, Annamaria

AU - Gafa, Sergio

AU - Rizzo, Francesco

AU - Coen, Massimo

AU - Tirelli, Umberto

AU - Caggese, Liliana

AU - Paparatti, Umberto Di Luzio

AU - Lazzarin, Adriano

PY - 1993/2

Y1 - 1993/2

N2 - Objective: To compare the effect of two dose regimens of zidovudine in the treatment of severe HIV-related thrombocytopenia (TP). Design: Eighty-four patients with severe HIV-related TP and platelet counts <50 × 109/l were enrolled in an open study at six centres. Patients were randomized into two groups to receive zidovudine (group A, 500 mg per day; group B, 1000 mg per day) for 6 months. Methods: Platelet counts were determined monthly and patients categorized as complete responders (CR; platelets > 100 × 109/l), partial responders (PR; platelets > 50 to <100 × 109/l), or failures (F; platelets to <50 × 109/l). CD4+ and CD8+ lymphocytes, HIV antigenaemia, β2-microglobulin, white blood cells, mean cell volume and haemoglobin were also determined. Results: Seventy-one patients (35 and 36 in groups A and B, respectively) completed the study; 11.4% of group A patients were CR and 45.7% PR; 38.9% of group B were CR and 33.3% PR. Increase in mean platelet counts was dose-related, more rapid in the higher dose group and remained significantly higher after 6 months of treatment (56.4 × 109/l in group A versus 98.2 × 109/l in group B; P <0.01). Conclusions: The results confirm the efficacy of zidovudine in the treatment of severe HIV-related TP. The average for CR and PR in the two groups was 64.8%; the higher dose of zidovudine was more effective at increasing platelet counts.

AB - Objective: To compare the effect of two dose regimens of zidovudine in the treatment of severe HIV-related thrombocytopenia (TP). Design: Eighty-four patients with severe HIV-related TP and platelet counts <50 × 109/l were enrolled in an open study at six centres. Patients were randomized into two groups to receive zidovudine (group A, 500 mg per day; group B, 1000 mg per day) for 6 months. Methods: Platelet counts were determined monthly and patients categorized as complete responders (CR; platelets > 100 × 109/l), partial responders (PR; platelets > 50 to <100 × 109/l), or failures (F; platelets to <50 × 109/l). CD4+ and CD8+ lymphocytes, HIV antigenaemia, β2-microglobulin, white blood cells, mean cell volume and haemoglobin were also determined. Results: Seventy-one patients (35 and 36 in groups A and B, respectively) completed the study; 11.4% of group A patients were CR and 45.7% PR; 38.9% of group B were CR and 33.3% PR. Increase in mean platelet counts was dose-related, more rapid in the higher dose group and remained significantly higher after 6 months of treatment (56.4 × 109/l in group A versus 98.2 × 109/l in group B; P <0.01). Conclusions: The results confirm the efficacy of zidovudine in the treatment of severe HIV-related TP. The average for CR and PR in the two groups was 64.8%; the higher dose of zidovudine was more effective at increasing platelet counts.

KW - Dose

KW - HIV-related thrombocytopenia

KW - Therapy

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0027419119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027419119&partnerID=8YFLogxK

M3 - Article

C2 - 8466682

AN - SCOPUS:0027419119

VL - 7

SP - 209

EP - 212

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 2

ER -